United Therapeutics Corporation and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, United Therapeutics Corporation and Arrowhead Pharmaceuticals, Inc. have demonstrated contrasting approaches in their Selling, General, and Administrative (SG&A) expenses.

From 2014 to 2023, United Therapeutics consistently allocated a significant portion of its budget to SG&A, peaking at nearly 487% of Arrowhead's spending in 2022. This reflects a robust commitment to marketing and administrative functions, possibly to support its expansive product portfolio. In contrast, Arrowhead Pharmaceuticals, while showing a steady increase in SG&A expenses, reached its highest in 2022, marking a 410% rise from 2014. This surge suggests a strategic pivot towards scaling operations and enhancing market presence.

Interestingly, data for United Therapeutics in 2024 is missing, leaving room for speculation on future trends. As these companies evolve, their spending patterns will continue to shape their competitive landscapes.